Thanks largely to the work of Sam Miller, the Orange County Register has one of the best baseball blogs of any newspaper in the country. The other bloggers, though, don’t always measure up, and Jeff Miller decided to take on Jim Thome’s 600th homer today, claiming that it’s just fine for us to assume he did steroids.
His big point to back it up?
“From 2001-03, Thome averaged 49 homers a year. He never hit more than 42 in any other season. A single statistic, a ton of suspicion.”
It’s a ton of something, alright.
I have no idea whether Jim Thome used steroids, but I strongly dislike it when amateurs go to the numbers to try to figure out when a guy was cheating. It’s a ridiculous exercise, particularly since there’s just no reason to think that taking an average player and juicing him up is going to add 10 or 20 homers to his year’s total. There’s simply no evidence that suggests that’s the case.
Anyway, Thome did peak in 2001-02. But to say Miller’s three-year span stands out from the rest of his career is nonsense. Let’s look at Thome’s at-bats per home run per year, ranked from top to bottom and only counting the seasons in which he had 300 plate appearances.
If Thome had exactly 500 at-bats at those rates in all of those seasons, he would have peaked at 54 homers in 2002. However, his next seven best seasons all would have come in between 40 and 47 homers and those seasons were spread out from 1997 to 2010.
So, go ahead, find the steroids seasons in there.
Brewers’ right-hander Phil Bickford received a 50-game suspension after testing positive for a drug of abuse, per the Los Angeles Times’ Bill Shaikin. This is the second time Bickford has been suspended for recreational drug use, as he was previously penalized in 2015 after testing positive for marijuana prior to the amateur draft.
Bickford was selected by the Giants in the first round of the 2015 draft and was later dealt to the Brewers for lefty reliever Will Smith at the 2016 trade deadline. He finished his 2016 campaign in High-A Brevard County, pitching to a 3.67 ERA, 10.0 K/9 rate and 5.0 BB/9 over 27 innings.
Two other suspensions were handed down on Friday, one to Toronto minor league right-hander Pedro Loficial for a positive test for metabolites of Stanozolol and one to Miami minor league outfielder Casey Soltis for a second positive test for drugs of abuse. Loficial will serve a 72-game suspension, while Soltis will serve 50 games. All three suspensions are due to start at the beginning of the 2017 season for each respective minor league team.
Brewers’ GM David Stearns issued a statement after the Commissioner’s Office announced Bickford’s suspension (via Vince Lara-Cinisomo of Baseball America):
We are very disappointed to learn of Phil’s suspension, but we fully support the Minor League Baseball Drug Prevention and Testing Program and its enforcement by the Commissioner’s Office. Phil understands he made a mistake, and we fully anticipate that he will learn from this experience.
Confirming a report from Tuesday, the Diamondbacks officially signed right-hander Fernando Rodney to a one-year, $2.75 million contract on Friday. The 39-year-old stands to receive up to $4 million in incentives, per Jack MacGruder of FanRag Sports, with $250,000 kicking in when the veteran reaches 40, 50 and 60 appearances and $500,000 if he reaches 70.
Rodney came three games shy of the 70-appearance mark in 2016 during back-to-back stints with the Padres and Marlins. He put up a cumulative 3.44 ERA on the year, which effectively disguised the extreme split during his performances in San Diego and Miami. The Diamondbacks aren’t anywhere close to contending in 2017, but Rodney should stabilize the back end of their bullpen while providing Arizona GM Mike Hazen with a potential trade chip during next year’s deadline.
Hazen issued a statement following the signing:
With Fernando, we’re getting an established Major League closer and a veteran presence in the bullpen. It is helpful to have someone with his experience on the back end to slow the game down and get the final three outs.